Global Coronary Artery Bypass Graft Surgery Pipeline Report 2022 Update - ResearchAndMarkets.com

The "Coronary Artery Bypass Graft Surgery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information about the Coronary Artery Bypass Graft Surgery pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Coronary artery bypass graft surgery devices are used in the surgery to improve blood flow to the obstructed coronary artery. Surgeons use these devices to treat people who have severe coronary heart disease.

Scope

• Extensive coverage of the Coronary Artery Bypass Graft Surgery under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Coronary Artery Bypass Graft Surgery and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Coronary Artery Bypass Graft Surgery under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Products under Development

3.1 Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development

3.2 Coronary Artery Bypass Graft Surgery - Pipeline Products by Territory

3.3 Coronary Artery Bypass Graft Surgery - Pipeline Products by Regulatory Path

3.4 Coronary Artery Bypass Graft Surgery - Pipeline Products by Estimated Approval Date

3.5 Coronary Artery Bypass Graft Surgery - Ongoing Clinical Trials

4 Coronary Artery Bypass Graft Surgery - Pipeline Products under Development by Companies

4.1 Coronary Artery Bypass Graft Surgery Companies - Pipeline Products by Stage of Development

4.2 Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development

5 Coronary Artery Bypass Graft Surgery Companies and Product Overview

5.1 AdvanSource Biomaterials Corporation Company Overview

5.2 ArtiFex Medical GmbH Company Overview

5.3 Axcelon Biopolymers Corp Company Overview

5.4 CardioPolymers Inc Company Overview

5.5 Cardious Inc Company Overview

5.6 Centre Hospitalier Universitaire de Nice Company Overview

5.7 Coromedic Ltd. Company Overview

5.8 Cytograft Tissue Engineering Inc (Inactive) Company Overview

5.9 Elana bv Company Overview

5.10 enVVeno Medical Corp Company Overview

5.11 Graft-Loc Inc. Company Overview

5.12 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview

5.13 iiTech BV Company Overview

5.14 McGill University Company Overview

5.15 Medical 21 Inc Company Overview

5.16 Myocardial Assist Systems and Technology LLC Company Overview

5.17 Neograft Technologies Inc Company Overview

5.18 PetVivo Holdings Inc Company Overview

5.19 Prekubator TTO Company Overview

5.20 RegenMedTX LLC Company Overview

5.21 Rox Medical Inc Company Overview

5.22 SeamVad Ltd. Company Overview

5.23 Surg Solutions SL Company Overview

5.24 Synovis Micro Companies Alliance Inc Company Overview

5.25 Thoratec LLC Company Overview

5.26 Tissue Regeneration Technologies LLC Company Overview

5.27 University College London Company Overview

5.28 University of Arizona Company Overview

5.29 University of California Davis Company Overview

5.30 University of California Los Angeles Company Overview

5.31 Xeltis AG Company Overview

6 Coronary Artery Bypass Graft Surgery- Recent Developments

6.1 May 03, 2022: Sanofi: Annual General Meeting of May 3, 2022

6.2 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022

6.3 Apr 28, 2022: LeMaitre Q1 2022 Financial Results

6.4 Apr 15, 2022: LeMaitre Will Announce First Quarter 2022 Earnings Results April 28, 2022

6.5 Apr 11, 2022: AtriCure to Announce First Quarter 2022 Financial Results

6.6 Feb 24, 2022: LeMaitre Q4 2021 Financial Results

6.7 Feb 11, 2022: LeMaitre Will Announce Fourth Quarter 2021 Earnings Results February 24, 2022

6.8 Jan 13, 2022: Getinge program recognizes dedicated North American vessel harvesters

6.9 Jan 04, 2022: Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference

6.10 Nov 17, 2021: French biotech CellProthera welcomes three exceptional talents to its executive management team

6.11 Nov 08, 2021: Boston Scientific Announces Upcoming Conference Schedule

6.12 Oct 28, 2021: Sanofi announces strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER

6.13 Oct 28, 2021: LeMaitre Q3 2021 Financial Results

6.14 Oct 27, 2021: Boston Scientific Announces Results For Third Quarter 2021

6.15 Oct 14, 2021: LeMaitre Will Announce Third Quarter 2021 Earnings Results on October 28, 2021

6.16 Sep 09, 2021: Etiometry and Terumo Cardiovascular announce partnership to deliver enhanced monitoring insights for adult cardiac surgery patients

6.17 Sep 09, 2021: Boston Scientific Announces 2021 Investor Day Meeting

6.18 Aug 04, 2021: AtriCure Reports Second Quarter 2021 Financial Results

6.19 Jul 30, 2021: AtriCure to Participate at the Canaccord 41st Annual Growth Conference

6.20 Jul 29, 2021: Sanofi announces half-year financial report for period ending June 30, 2021

6.21 Jul 29, 2021: LeMaitre Q2 2021 Financial Results

6.22 Jul 27, 2021: Cardiovascular Systems to Attend Three Investor Conferences in August

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/gzg7mn

Source: GlobalData

View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005569/en/